Pharmacist knowledge of gout management: impact of an educational intervention.

Crystal arthritis Education Gout Multi-disciplinary care

Journal

BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571

Informations de publication

Date de publication:
23 May 2022
Historique:
received: 28 11 2021
accepted: 09 03 2022
entrez: 22 5 2022
pubmed: 23 5 2022
medline: 23 5 2022
Statut: epublish

Résumé

Pharmacists play a key role in community gout education. We investigated pharmacist knowledge of gout management and developed an educational intervention which was assessed in a cohort of Irish pharmacists. A ten-question questionnaire about gout management was developed to assess pharmacists' knowledge. A 14 min 26 s video educational intervention was co-designed by a rheumatologist, a pharmacist, and designer of pharmacy education resources. The effectiveness of this pharmacy-specific intervention was assessed using the same questionnaire in 53 pharmacists (25 in the intervention group; 28 in the control group). Contingency tables were used to analyse differences between groups. There were 173 pharmacist respondents to the initial survey; 35.3% answered that first-line therapy for gout involves a combination of a xanthine oxidase inhibitor (e.g., allopurinol) combined with a prophylactic agent (e.g., colchicine), and 28.9% of respondents answered that colchicine prophylaxis should be used when initiating urate-lowering therapy. Following the educational intervention, pharmacist's knowledge about gout management increased across many domains, including serum urate targets when using urate-lowering therapy (p = 0.006), use of colchicine prophylaxis (p = 0.011), and duration of colchicine use (p < 0.001). Gout management recommendations can be impeded if translation into pharmacy practice is neglected. Pharmacists are a valuable information resource for patients. Co-designing a brief education intervention with pharmacists is an effective, low-cost way to increase pharmacist knowledge on the management of gout.

Sections du résumé

BACKGROUND BACKGROUND
Pharmacists play a key role in community gout education. We investigated pharmacist knowledge of gout management and developed an educational intervention which was assessed in a cohort of Irish pharmacists.
METHODS METHODS
A ten-question questionnaire about gout management was developed to assess pharmacists' knowledge. A 14 min 26 s video educational intervention was co-designed by a rheumatologist, a pharmacist, and designer of pharmacy education resources. The effectiveness of this pharmacy-specific intervention was assessed using the same questionnaire in 53 pharmacists (25 in the intervention group; 28 in the control group). Contingency tables were used to analyse differences between groups.
RESULTS RESULTS
There were 173 pharmacist respondents to the initial survey; 35.3% answered that first-line therapy for gout involves a combination of a xanthine oxidase inhibitor (e.g., allopurinol) combined with a prophylactic agent (e.g., colchicine), and 28.9% of respondents answered that colchicine prophylaxis should be used when initiating urate-lowering therapy. Following the educational intervention, pharmacist's knowledge about gout management increased across many domains, including serum urate targets when using urate-lowering therapy (p = 0.006), use of colchicine prophylaxis (p = 0.011), and duration of colchicine use (p < 0.001).
CONCLUSION CONCLUSIONS
Gout management recommendations can be impeded if translation into pharmacy practice is neglected. Pharmacists are a valuable information resource for patients. Co-designing a brief education intervention with pharmacists is an effective, low-cost way to increase pharmacist knowledge on the management of gout.

Identifiants

pubmed: 35599318
doi: 10.1186/s41927-022-00259-x
pii: 10.1186/s41927-022-00259-x
pmc: PMC9125937
doi:

Types de publication

Journal Article

Langues

eng

Pagination

30

Subventions

Organisme : A.Menarini Pharmaceuticals Ireland
ID : Educational Grant

Informations de copyright

© 2022. The Author(s).

Références

Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-760
pubmed: 32391934
Psychol Sci. 2014 Mar;25(3):639-47
pubmed: 24444515
Ann Fam Med. 2018 Nov;16(6):515-520
pubmed: 30420366
BMJ Open. 2018 Apr 10;8(4):e017542
pubmed: 29643150
Am J Med. 2019 Mar;132(3):354-361
pubmed: 30503879
Addict Sci Clin Pract. 2019 Sep 2;14(1):30
pubmed: 31474225
Ann Rheum Dis. 2017 Jan;76(1):29-42
pubmed: 27457514
Pharmacy (Basel). 2019 Sep 25;7(4):
pubmed: 31557795
J Clin Rheumatol. 2011 Aug;17(5):242-8
pubmed: 21778899
Nat Rev Rheumatol. 2015 Nov;11(11):649-62
pubmed: 26150127
Int J Qual Health Care. 2003 Jun;15(3):261-6
pubmed: 12803354
Lancet. 2016 Oct 22;388(10055):2039-2052
pubmed: 27112094
Public Health. 1992 May;106(3):231-7
pubmed: 1603927
Nat Rev Dis Primers. 2019 Sep 26;5(1):69
pubmed: 31558729

Auteurs

Emma R Dorris (ER)

UCD School of Medicine, University College Dublin, Dublin, Ireland. emma.dorris@ucd.ie.

Mariosa Kieran (M)

Pharmacy Department, Mater Misericordiae University Hospital, Dublin, Ireland.

Nicola Dalbeth (N)

Department of Medicine, University of Auckland, Auckland, New Zealand.

Geraldine McCarthy (G)

UCD School of Medicine, University College Dublin, Dublin, Ireland.
Department of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland.

Classifications MeSH